Intercept Pharmaceuticals, whose NASH drug candidate went from frontrunner to also-ran, is being acquired for $794 million by an Italian company that sees the biotech’s remaining assets as a way to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback